Our biopharma portfolio

We are building a biosimilar portfolio across multiple disease areas, including autoimmune diseases, cancer, hematology, osteoporosis and other areas of high healthcare need. Our goal is to help expand access to high-quality biologic medicines while supporting more sustainable healthcare systems.

Biopharma approved products

Product

Molecule / active substance

Class / target 

IDACIO®adalimumabTNFα monoclonal antibody
BOMYNTRA®denosumabRANKL monoclonal antibody
CONEXXENCE®denosumabRANKL monoclonal antibody
STIMUFEND®pegfilgrastimG-CSF analogue
TYENNE®tocilizumabIL-6 receptor monoclonal antibody
OTULFI®ustekinumabIL-12 / IL-23 monoclonal antibody

Biopharma pipeline

Our pipeline includes more than 15 biosimilar assets in development across major therapeutic areas.

Therapeutic area 

Example focus 

Autoimmune diseasesImmunology, inflammatory and gastroenterology conditions 
Bone healthOsteoporosis and related conditions
EndocrinologyChronic metabolic conditions
HematologyBlood disorders
OncologyCancer and supportive care 
OphthalmologyRetinal diseases
Respiratory diseasesSevere inflammatory respiratory conditions 

Important information about prescription medicines

We cannot provide detailed information about our prescription medicines on this global website, in compliance with applicable regulations.

Our medicines are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local Fresenius Kabi websites to find out more about our medicines. Please note that in some countries we are not allowed to provide detailed, or sometimes any information on prescription medicines. Please seek information from reliable local sources and always ask a healthcare professional for advice about medicines.

Reporting side effects

The safety of patients is very important to us. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

By reporting side effects, you can help provide more information on the safety of medicines. You can report a possible side effect to Fresenius Kabi using the Report side effect link below.

Report Adverse Event